Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cells + interferon gamma
- Development stage
- Unknown
- Lead developer
- Army Specialized Medical Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This experimental cell therapy consists of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) that have been pre-activated or "primed" with the pro-inflammatory cytokine interferon-gamma (IFN-gamma). Developed by the Research Institute of Surgery at Daping Hospital (Third Military Medical University), this approach aims to enhance the therapeutic potential of MSCs for autoimmune conditions like rheumatoid arthritis. Priming with IFN-gamma "licenses" the MSCs, significantly upregulating the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme that plays a critical role in immunosuppression by depleting tryptophan and producing kynurenines. This mechanism leads to the inhibition of T-cell proliferation and the modulation of the Th17/Treg balance, shifting the immune environment from a pro-inflammatory state toward immune tolerance. The therapy is typically administered systemically to reduce joint inflammation and prevent bone erosion in patients with rheumatoid arthritis.
- Other names
- IFN-gamma-primed human umbilical cord-derived mesenchymal stem cellsIFN-gamma-pretreated hUC-MSCsIFN-gamma-licensed hUC-MSCs
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cells + interferon gamma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells + interferon gamma.